Prostate cancer is the most commonly diagnosed solid organ malignancy for men in the US and remains the second leading cause of cancer deaths for this population. While PSA screening has greatly improved early detection, its lack of specificity has led to unnecessary biopsies and marked over-diagnosis and over-treatment. Multiple tools and strategies have been developed which more accurately detect clinically significant prostate cancer. Multi-parametric MRI (mpMRI) use prior to biopsy, for example, has been shown in randomized controlled trials to reduce unnecessary biopsies while better detecting clinically significant disease. Serum tests, like the prostate health index (PHI), can additionally limit unnecessary biopsies. While the advantages of advanced testing with mpMRI or other tools prior to biopsy is clear, adoption of these practices has not been thoroughly studied in routine clinical practice. Here we aim to evaluate the use of advanced prostate cancer detection methods and in particular mpMRI as a risk assessment tool in our larger Northwestern (NMH) healthcare system, which includes 9 hospitals covering both academic and community hospitals spanning over 4 regions across Illinois.
|Effective start/end date||7/1/21 → 6/30/22|
- Urology Care Foundation, Inc. (Award Letter 7/14/21)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.